- Mylan (MYL +4.6%) hits another fresh high as the FDA's guidance regarding generic versions of Glaxo's (GSK) Advair strikes optimism that the generic-drug maker will one day get clearance to sell its own soon.
- Up to now, no generic competitor to Advair has emerged because it's been unclear what would be required by regulators in order to win approval.
- The FDA’s new guidelines now make it possible for Advair rivals to hit the market by 2016 or 2017.
- MYL is considered one of the most viable companies to develop an Advair competitor.
Mylan gets a boost from the FDA's new guidelines for generic versions of Advair
Sep 10 2013, 15:56 ET